Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

Fineline Cube Jul 20, 2026
Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Fineline Cube Jul 17, 2026
Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Policy / Regulatory

Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms

Fineline Cube Jul 20, 2026
Company Drug

CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years

Fineline Cube Jul 20, 2026
Company Drug

Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia

Fineline Cube Jul 20, 2026
Policy / Regulatory

China’s NMPA Issues Guidelines for Onsite Inspections of Medical Device Companies

Fineline Cube Jul 31, 2024

The National Medical Products Administration (NMPA) of China has released the “Guidelines for Onsite Inspection...

Company

WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges

Fineline Cube Jul 30, 2024

China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued...

Company Deals

Roche Completes Acquisition of LumiraDx’s Point-of-Care Solutions Business

Fineline Cube Jul 30, 2024

Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO) has announced the...

Company

Philips Posts 2% Q2 2024 Sales Growth, Boosted by North American Demand

Fineline Cube Jul 30, 2024

Royal Philips (NYSE: PHG), the Dutch electronics giant, reported its financial results for the second...

Company Deals

GSK Enters into Strategic Partnership with Flagship Pioneering to Develop Novel Medicines and Vaccines

Fineline Cube Jul 30, 2024

UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with...

Company Drug

Novartis’s Scemblix Receives FDA Priority Review for First-Line CML Treatment

Fineline Cube Jul 30, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the US Food and Drug Administration...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-A1921 Clinical Study in Advanced Solid Tumors

Fineline Cube Jul 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

Porton Pharma Solutions Partners with Guangzhou Geneseed Biotech to Advance circRNA Therapies

Fineline Cube Jul 30, 2024

Porton Pharma Solutions Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Company Medical Device

ShuWen Biotech’s Preeclampsia Self-Test Receives NMPA Approval, Marking a Global First

Fineline Cube Jul 30, 2024

Zhejiang-based ShuWen Biotech Co., Ltd has announced that it has received marketing approval from China’s...

Company Deals

Livzon Pharmaceutical Group to Establish Joint Venture with PT Kalbe Farma in Indonesia

Fineline Cube Jul 30, 2024

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced plans to form a joint venture...

Company Drug

Organon’s Liptruzet Launches in China for Hypercholesterolemia Treatment

Fineline Cube Jul 30, 2024

US pharmaceutical company Organon (NYSE: OGN) has announced the official market launch of its single-tablet...

Company Deals

LTZ Therapeutics Secures Over USD 20 Million in Series A Financing to Advance Immunotherapy Pipeline

Fineline Cube Jul 30, 2024

LTZ Therapeutics Inc., a biotechnology company specializing in immunotherapy with operations in both the US...

Company Medical Device

Shanghai Sanyou Medical Gains NMPA Approval for 3D Printed Cervical Fusion Device

Fineline Cube Jul 30, 2024

Shanghai Sanyou Medical Co., Ltd (SHA: 688085), a prominent player in the medical device industry...

Company Deals

Guangzhou Red Pine Medical Secures Series D Funding to Accelerate Global Expansion

Fineline Cube Jul 30, 2024

Guangzhou Red Pine Medical Instrument Co., Ltd., a leading company in the disposable endoscope sector,...

Policy / Regulatory

China’s H1 2024 Pharmaceutical Trade Data Indicates Mixed Performance in Global Markets

Fineline Cube Jul 30, 2024

The Ministry of Industry and Information Technology (MIIT) has released a report on the first...

Policy / Regulatory

China’s NHC Reports 2023 County Hospital Medical Service Capability Evaluation Results

Fineline Cube Jul 30, 2024

The National Health Commission (NHC) of China has released a notice detailing the results of...

Company Drug

EU Regulator Rejects Marketing Authorization for Biogen and Eisai’s Alzheimer’s Drug Leqembi

Fineline Cube Jul 29, 2024

Biogen Inc. (NASDAQ: BIIB), a US biotechnology company, and its Japanese counterpart Eisai Co., Ltd...

Policy / Regulatory

Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement

Fineline Cube Jul 29, 2024

Yipinhong Pharmacy Co., Ltd (SHE: 300723), a China-based pharmaceutical company, has made a significant repayment...

Company Drug

Luye Pharma’s Antipsychotic Erzofri Gains FDA Nod for Schizophrenia Treatment

Fineline Cube Jul 29, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has achieved a...

Company

AstraZeneca Charts Comprehensive Anti-Obesity Strategy with GLP-1 and Amylin Therapies

Fineline Cube Jul 29, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has outlined its strategic advancements and future...

Posts pagination

1 … 353 354 355 … 697

Recent updates

  • Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms
  • China’s NMPA Suspends Medochemie’s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure
  • CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years
  • Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China
  • Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms

Policy / Regulatory

China’s NMPA Suspends Medochemie’s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure

Company Drug

CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years

Company Deals

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.